Research output per year
Research output per year
Personal profile
Biography
- Biograpy: Obtained his PhD in Hungary at University of Debrecen, where he became fascinated by biophysical techniques that he learned to use to study molecular interactions in living cells. He was further trained in the Babraham Institute In Cambridge (UK) and later at the ErasmusMC in Rotterdam (NL) where he as postdoctoral fellow has studied the molecular needs of genetic engineering of T cells for the immunotherapy of cancer. He continued his career at the UMCU in Utrecht, where he was appointed in 2014 as staff member of Section Applied within the Laboratory of Translational Immunology. He is currently focusing on the developement of novel gamma delta T cell-based immunotherapies and the better understanding of innate T cell and tumour cell interactions. Reserach interest: Tumour recognition of innate immune cells, Immune receptors , Genetic engineering
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: Collaborative translation of scientific discoveries into advanced treatments for neurological rare genetic diseases and cancer
Marolt Presen, D., Lainšček, D., Kinghorn, J., Sebestyen, Z., Kuball, J., Amini, L., Reinke, P., Fuchs, A., Jerala, R. & Benčina, M., Jan 2025, In: Computational and Structural Biotechnology Journal. 27, p. 10-16 7 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Downloads (Pure) -
BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response
Alieva, M., Barrera Román, M., de Blank, S., Petcu, D., Zeeman, A. L., Dautzenberg, N. M. M., Cornel, A. M., van de Ven, C., Pieters, R., den Boer, M. L., Nierkens, S., Calkoen, F. G. J., Clevers, H., Kuball, J., Sebestyén, Z., Wehrens, E. J., Dekkers, J. F. & Rios, A. C., Jul 2024, In: Nature protocols. 19, 7, p. 2052-2084 33 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML
Lo Presti, V., Meringa, A., Dunnebach, E., van Velzen, A., Moreira, A. V., Stam, R. W., Kotecha, R. S., Krippner-Heidenreich, A., Heidenreich, O. T., Plantinga, M., Cornel, A., Sebestyen, Z., Kuball, J., van Til, N. P. & Nierkens, S., 5 Apr 2024, In: Journal for ImmunoTherapy of Cancer. 12, 4, 15 p., e008174.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile21 Downloads (Pure) -
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
Hernández-López, P., van Diest, E., Brazda, P., Heijhuurs, S., Meringa, A., Hoorens van Heyningen, L., Riillo, C., Schwenzel, C., Zintchenko, M., Johanna, I., Nicolasen, M. J. T., Cleven, A., Kluiver, T. A., Millen, R., Zheng, J., Karaiskaki, F., Straetemans, T., Clevers, H., de Bree, R. & Stunnenberg, H. G. & 6 others, , Jan 2024, In: Nature immunology. 25, 1, p. 88-101 14 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
Cornel, A. M., van der Sman, L., van Dinter, J. T., Arrabito, M., Dunnebach, E., van Hoesel, M., Kluiver, T. A., Lopes, A. P., Dautzenberg, N. M. M., Dekker, L., van Rijn, J. M., van den Beemt, D. A. M. H., Buhl, J. L., du Chatinier, A., Barneh, F., Lu, Y., Lo Nigro, L., Krippner-Heidenreich, A., Sebestyén, Z. & Kuball, J. & 6 others, , 21 Mar 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3, 15 p., e007538.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile7 Downloads (Pure)
-
Exploring Vγ9Vδ2 T Cells & Receptors
Z Sebestyen (Invited speaker)
30 Sept 2020Activity: Talk or presentation › Invited talk › Professional
-
Targeting solid tumors with TEGs
Z Sebestyen (Speaker)
16 Jan 2020Activity: Talk or presentation › Invited talk › Academic
-
Targeting cancer as metabolic disease through T-cells engineered to express defined Gamma Delta TCR
Z Sebestyen (Invited speaker)
24 Feb 2019Activity: Talk or presentation › Invited talk › Academic
-
A new generation of CART cells in cancer: TEGs
Z Sebestyen (Speaker)
23 Mar 2018Activity: Talk or presentation › Invited talk › Academic
-
Reality check on gdT cells: from bench to bedside
Z Sebestyen (Speaker)
17 Mar 2017Activity: Talk or presentation › Invited talk › Academic
Prizes
-
Dutch Cancer Society/KWF Unique High Risk Project: Empowering the T cell killing machinery to eradicate cancer cells and prevent outgrowth.
Peperzak, V. (Recipient) & Sebestyen, Z. (Recipient), 2018
Prize: Fellowship awarded competitively
-
KWF/Alpe d'HuZes Research Project grant: Optimized Killing (OK) technology to empower engineered T or NK cells in the treatment of cancer.
Peperzak, V. (Recipient) & Sebestyen, Z. (Recipient), 2020
Prize: Fellowship awarded competitively